Accelerate to discover

Homepage>Discover>Assessment of pro-arrhythmic effects using xCELLigence Cardio system and Pluricyte Cardiomyocytes

Back to filter

Jun 27, 2024

Watch this pre-recorded webinar with Dr. Andrew Van Praagh to learn how our new Aura software feature —Kinetics—...

Theranostics: From Mice to Men and Back

Jun 25, 2024

Recorded webinar
Presenters: Prof. Dr. Ken Herrmann and Prof. Dr. Katharina Lückerath – Moderator: Hannah Notebaert

Orion 2024 AACR poster: 17-plex single-step stain and imaging of cell Lung Carcinoma

Jun 21, 2024

RareCyte Orion is a benchtop, high resolution, whole slide multimodal imaging instrument. A combination of quantitative...

New release now available: Cytek Amnis AI v3.0 Software

Jun 17, 2024

The new Cytek Amnis AI v3.0 image analysis software features an integrated transfer learning algorithm, an option to...

Jul 3, 2024

Cytek webinar: Imaging Flow Cytometry for Chromosomal Assessment in Hematological Malignancies

Jun 7, 2024

In this webinar, we will describe a new innovative approach we developed that resolves these limitations. The method...

Hypoxia in the Tumor Immune Microenvironment (TIME)

Jun 6, 2024

Thursday, 11 July 2024, 16:00 CET | 10:00 EST
Zaver M. Bhujwalla, PhD...

X-RAD 320 for irradiation therapy during quantifying study for in vivo collagen reorganization

Jun 5, 2024

Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation...

Jul 3, 2024

Use of MRI and microCT to evaluate gene therapy for the treatment of discogenic back pain

Jun 4, 2024

MRI images were obtained using the 9.4T Bruker BioSpec system, equipped with 40 mm 1H quadrature volume resonator, and...

Show all topics (10)

Assessment of pro-arrhythmic effects using xCELLigence Cardio system and Pluricyte Cardiomyocytes

Aug 21, 2019

This application note describes our recommendations for the analysis of Pluricyte Cardiomyocytes electrophysiology by MEA and impedance measurements using the xCELLigence RTCA Cardio ECR system (ACEA Biosciences). In addition, a case study describing the assessment of the effects of a set of pro-arrhythmic compounds in Pluricyte Cardiomyocytes, showing the expected pharmacological responses, is provided in this document. Cardiomyocytes, cultured in Pluricyte Cardiomyocyte Medium, in combination with the xCELLigence RTCA CardioECRsystem provide a highly relevant in vitro assay platform to study the cardiac safety profile of compounds during drug development.